Cover Image

The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry

We analyzed 368 chronic lymphocytic leukemia patients who underwent allogeneic hematopoietic stem cell transplantation reported to the EBMT registry between 1995 and 2007. There were 198 human leukocyte antigen (HLA)-identical siblings; among unrelated transplants, 31 were well matched in high resol...

Full description

Saved in:
Bibliographic Details
Main Authors: Michallet, Mauricette (Author) , Sobh, M. (Author) , Milligan, D. (Author) , Morisset, S. (Author) , Niederwieser, D. (Author) , Koza, V. (Author) , Ruutu, T. (Author) , Russell, N. H. (Author) , Verdonck, L. (Author) , Dhedin, N. (Author) , Vitek, A. (Author) , Boogaerts, M. (Author) , Vindelov, L. (Author) , Finke, J. (Author) , Dubois, V. (Author) , Biezen, A. van (Author) , Brand, R. (Author) , Witte, T. de (Author) , Dreger, Peter (Author)
Format: Article (Journal)
Language:English
Published: 12 August 2010
In: Leukemia
Year: 2010, Volume: 24, Issue: 10, Pages: 1725-1731
ISSN:1476-5551
DOI:10.1038/leu.2010.165
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/leu.2010.165
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/leu2010165
Get full text
Author Notes:M Michallet, M Sobh, D Milligan, S Morisset, D Niederwieser, V Koza, T Ruutu , NH Russell, L Verdonck, N Dhedin, A Vitek, M Boogaerts, L Vindelov, J Finke, V Dubois, A van Biezen, R Brand, T de Witte and P Dreger on behalf of the Chronic Leukemia Working Party of the EBMT
Description
Summary:We analyzed 368 chronic lymphocytic leukemia patients who underwent allogeneic hematopoietic stem cell transplantation reported to the EBMT registry between 1995 and 2007. There were 198 human leukocyte antigen (HLA)-identical siblings; among unrelated transplants, 31 were well matched in high resolution (‘well matched’ unrelated donor, WMUD), and 139 were mismatched (MM), including 30 matched in low resolution; 266 patients (72%) received reduced-intensity conditioning and 102 (28%) received standard. According to the EBMT risk score, 11% were in scores 1-3, 23% in score 4, 40% in score 5, 22% in score 6 and 4% in score 7. There was no difference in overall survival (OS) at 5 years between HLA-identical siblings (55% (48-64)) and WMUD (59% (41-84)), P=0.82. In contrast, OS was significantly worse for MM (37% (29-48) P=0.005) due to a significant excess of transplant-related mortality. Also OS worsened significantly when EBMT risk score increased. HLA matching had no significant impact on relapse (siblings: 24% (21-27); WMUD: 35% (26-44), P=0.11 and MM: 21% (18-24), P=0.81); alemtuzumab T-cell depletion and stem cell source (peripheral blood) were associated with an increased risk. Our findings support the use of WMUD as equivalent alternative to HLA-matched sibling donors for allogeneic HSCT in CLL, and justify the application of EBMT risk score in this disease.
Item Description:Gesehen am 21.04.2023
Physical Description:Online Resource
ISSN:1476-5551
DOI:10.1038/leu.2010.165

Similar Items